Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study

NCT02472717 · Withdrawn

Last updated 2026-05-28

This clinical trial tested whether the medication liraglutide, given for 12 weeks, improves symptoms in adults with psoriatic arthritis compared to a placebo.

Status Withdrawn Stopped before any participant enrolled.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Who can join Ages 18–70 · all sexes

Timeline Started 2015-05 · est. completion 2016-10

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT02472717 ↗

Description as written by the study sponsor.

Exploratory, double-blind randomized, placebo-controlled, Phase II study to evaluate the effect(s) of short-term administration of liraglutide, a GLP-1R (glucagon-like peptide-1 receptor) agonist on joint and skin inflammation in patients with active Psoriatic Arthritis.

Treatments tested

liraglutide also known as Victoza Drug

Liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
Placebo Other

Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm

Main thing measured	The change in the proportion of patients achieving an ACR 20% improvement response in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to placebo
Sponsor	University Health Network, Toronto
Conditions studied	Psoriatic Arthritis, Psoriasis, Impaired Glucose Tolerance, Type 2 Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02472717 ↗